Mice and rats trained after treatment with cycloheximide or acetoxycycloheximide in a conditioned avoidance response develop an amnesia of their training experience. This amnesia has been attributed to the profound inhibition of protein synthesis caused by the two antibiotics. Evidence is presented that additionally the antibiotics inhibit the activity of tyrosine hydroxylase, a finding that suggests that their amnestic effect may be due in part to reduction of the functional pool of norepinephrine.
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Cycloheximide (CXM) and acetoxycycloheximide (AXM), powerful inhibitors of protein synthesis, have been used in studies of memory in mice and rats to test the possibility that synthesis of protein is essential for the establishment and maintenance of memory. One procedure has been to train animals in an active or passive avoidance task at a time after the injection of the antibiotic when inhibition of protein synthesis is profound. Under these circumstances a permanent or transient amnesia develops within the first day, and often within several hours after training (1) (2) (3) (4) (5) (6) .
Our studies in mice with another antibiotic, puromycin, suggested that the amnesia produced by this antibiotic when it is injected a day or more after training is due to blockage of central adrenergic synapses, and is not the result of its drastic inhibition of protein synthesis (7) . In view of this experience, we have considered the possibility that the amnesia caused by CXM and AXM might also in part be due to side effects on the adrenergic system. Our first test of this possibility was made with rats injected intracerebrally with AXM that were subsequently, at the height of inhibition of protein synthesis, trained in a brightness discrimination task. These rats were consistently amnesic 24 hr after training, but had recovered memory spontaneously within an additional 5 days (4). Intraperitoneal injection (before or after training or before retention testing) of agents that release norephinephrine from its storage sites eliminated the amnesia (8) , an effect consistent with the possibility that they had restored a depleted functional fraction of norepinephrine.
The present experiments were done to further test our working hypothesis. The activities of cerebral tyrosine hydroxylase, dopa decarboxylase (EC 4.1.1.26), and choline acetyltransferase (EC 2.3.1.6) were measured in rats injected intracerebrally with AXM and/or mice injected subcutaneously with CXM. Both antibiotics were used at a dosage that leads to amnesia. We chose tyrosine hydroxylase for study because it appears to be rate-limiting in the synthesis of norepinephrine (9) . The finding that the activity of this enzyme is reduced by both antibiotics led us to measure the activity of dopa decarboxylase, a second enzyme involved in the synthesis of norepinephrine. Finally, we were concerned with the possibility that the antibiotics might inhibit choline acetyltransferase, and so reduce the functional pool of acetylcholine.
Male Fisher rats (Microbiological Associates, 250-300 g) and Swiss Webster female mice (Huntington Farms, 30-35 g) were used. Rats received bitemporal injections (4) of AXM containing 20 ,ug of AXM in 50 Ml of 0.15 M NaCl per site, or corresponding injections of saline under halothane (Ayerst) anesthesia administered by mask. Experimental mice received subcutaneous injections of CXM (120 mg/kg) in water, and controls received normal saline. In rats, a sample consisting of the neocortex, entorhinal cortex, and hippocarupus was taken for assay of enzyme activities; in mice, the whole of the cerebral hemispheres was used.
Assays for tyrosine hydroxylase activity followed, with some modifications, the method of Nagatsu et al. (10) . Tissues were homogenized in ice-cold 13 mM potassium phosphate buffer (pH 7.0) (1/4.5 w/v) containing, for rats, 0.5% sodium deoxycholate and for mice, 1% Triton X-100 (11). The homogenates were centrifuged at 30,000 X g for 10 min. The incubation medium for the enzyme assay consisted of 200 Mmol of sodium acetate buffer (pH 6.1); 1500 units of catalase (Sigma); 25 nmol of L-[3,5-3H Ityrosine (400,000 cpm; New England Nuclear Nuclear Corp., 1 mCi/4 Mg); and 0.05 ml of 10% 2-mercaptoethanol containing 500 nmol of 6,7-dimethyl-5,6,7,8-tetrahydropterine HCl (Calbiochem). The reaction, at 370, was started by the addition of 0.3 ml of the supernatant fluid from the homogenates, to give a final volume of reaction mixture of 0.53 ml. Blanks consisted of all the above reagents, with 13 mM potassium phosphate buffer (pH 7.0) substituted for the tissue supernatant fluids. Assays and blanks were run in duplicate. The reaction was stopped by the addition of 0.3 ml of 10% trichloroacetic acid after 15 min with rat tissue and after 12 min with mouse tissue. Over these intervals the rate of formation of reaction product was proportional to the amount of enzyme obtained from control brains.
Tissue tyrosine was determined by the method of Waalkes and Udenfriend (12) . When the tissue concentration of tyrosine was modified by CXM or AXM, rates of oxidation were corrected to levels of tyrosine in control assays from curves 354 Abbreviations: CXM, cycloheximide; AXM, acetoxycycloheximide; Me2H4 pterine 6,7-dimethyl-5,6,7,8-tetrahydropterine HCl.
relating rate of tyrosine oxidation to substrate concentration (Fig. 1) . Control assays in rats and mice contained 33 and 29 nmol of tyrosine, respectively.
The assay for choline acetyltransferase followed strictly that described by Schrier and Shuster (13) , except that acetone extraction of the enzyme from brain was effected with a motor-driven homogenizer rather than a Waring Blendor. Assays were run in duplicate or triplicate. Dopa decarboxylase activity was measured precisely as described by Christenson et al. (14) , with 3 mM -dopa as substrate.
The concentration of cerebral tyrosine was clearly increased in mice after subcutaneous injection of CXM, and in rats after intracerebral injection of AXM. The control values for mice averaged 13 Ag/g. From 30 min to 4 hr after treatment with CXM the values averaged 31 gg/g, without apparent variation during this period. Samples of neocortex, entorhinal cortex, and hippocampus from untreated rats contained 14 ug/g of tyrosine. From 1.5 to 2.5 hr after intracerebral injection of saline or AXM, the values were 18 Ag/g and 34 Mg/g, respectively. Substantially larger increases in brain tyrosine concentration, attributed to inhibition of protein synthesis, were found by Dariman (15) in rats 4 hr after intraperitoneal injection of CXM.
The results of the enzyme assays are shown in Table 1 .
Intracerebral injection of AXM in rats was followed by a 46%
loss of activity of tyrosine hydroxylase observed 1.5-2.5 hr after the injection. Preliminary experiments indicated that significant loss of activity was confined to this period. The activity of dopa decarboxylase assayed at 1 hr (n = 3), 2 hr (n = 3), and 3 hr (n = 3) showed no significant change after treatment with AXM. In mice, subcutaneous injections of CXM gave results similar to those found in rats. Loss of tyrosine hydroxylase activity, amounting to about 20%0, was first observed 1 hr after the injection and persisted for 1 hr; this loss was followed by a marginally significant increase in activity at [3] [4] hr. Activities of choline acetyltransferase were normal over the 3 hr after treatment.
The loss of activity of tyrosine hydroxylase apparently is due to inhibition, rather than reduction, of synthetic rate, since our AXM injections depress protein synthesis more than 90% for 6 hr (4), a period exceeding that of decreased enzyme activity. Recovery of tyrosine hydroxylase while protein synthesis is drastically suppressed indicates additionally that the inhibition of enzyme activity is reversible. Two sets of experiments were done with mice to understand better the nature of the inhibition. In one, CXM was added to enzyme (9) Acetyltrans-10. Student's t-test was used for statistical comparisons.
* Values of n, the number of animals tested, are given in parentheses.
t NS, not significant.
prepared from untreated brain; inhibition was absent. In the second, measurements were made of the effect of the 2 substrates, tyrosine and 6,7-dimethyl-5,6,7,8-tetrahydropterineHCl(Me2H4 pterine) on the reaction velocity of enzyme prepared from untreated and CXM-exposed brains. Fig. 1 gives a plot of the reciprocal of the velocity (V) against the reciprocal of the tyrosine concentration, at a constant concentration of Me2H4 pterine (0.32 mM) present throughout. The apparent Km (60 MM) was the same with both preparations, while Vmax of the control enzyme exceeded that from the CXM-exposed brain. Similar results were obtained when velocities were measured in the presence of a constant concentration of tyrosine (40 /.M), but with various concentrations of Me2H4 pterine. Tyrosine hydroxylase from the brains of untreated and treated mice had identical Km values (500 MM), while Vmax of the enzyme from the untreated exceeded that of the treated brain.
As seen in Fig. 1 , cerebral tyrosine hydroxylase obtained from mice treated with CXM demonstrates noncompetitive kinetics, but this finding does not exclude the possibility of structural modification of the enzyme molecule leading to a decrease in Vmax. The absence of an effect when CXM was added to the assay mixture containing enzyme from untreated mice suggests that a metabolic product of CXM may have been responsible for the inhibition. O-O, CXM-treated.
The relationship between the inhibition of tyrosine hydroxProc. Nat. Acad. Sci. USA 70 (1978) ylase activity that we have noted and the amnestic effects of the glutarimide antibiotics is unclear. If AXM and CXM deplete the functional pool of norepinephrine sufficiently to affect memory, their inhibitory effects in vivo should last longer and, with respect to CXM at least, be more profound than has been found in our in vitro studies. Several possibilities suggest that this situation may exist. Our results give the average effect on large samples of the cerebral hemispheres; critical regions may be more severely affected. Dilution of an enzyme-inhibitor complex by the preparative and assay procedures that we have used would be expected to lead to its dissociation, and so to give an underestimation of the inhibition present in vivo. It is not known whether dihydropteridine reductase and dopamine 3-hydroxylase, other enzymes involved in the synthesis of catecholamines, are also inhibited. An additional interesting possibility is based on the work of Shiman et al. (16) , who reported marked differences between the properties of purified tyrosine hydroxylase in the presence of its naturally occurring cofactor, tetrahydrobiopterin, and the synthetic analogue, Me2H4 pterine. Most immediately pertinent to our situation is their observation that the enzyme with tetrahydrobiopterin present is 30% inhibited in vitro at only twice the normal tissue concentration of tyrosine. Dairman (15) , however, in experiments in vivo has failed to find evidence that this analogue effect occurs in rat brain. To test the combined effect of these possibilities on the functional pool of norepinephrine, studies of the rate of synthesis of the catecholamine after treatment with AXM and CXM appear desirable.
Our present findings do, however, indicate that side reactions of AXM and CXM cannot be ignored, and that caution should be used in attributing their amnestic effects solely to inhibition of protein synthesis. This view has also been expressed by Randt et al. (17) , who observed in mice that an increase in the dose of CXM administered from 3 to 5 mg led to increased amnesia without significantly increasing inhibition of protein synthesis.
